People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Pharmaceuticals, Other Technology, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alimera Sciences Inc | — | Pharmaceuticals | Series C | $173.8M | $1.1B | 2009 |
| Oraya Therapeutics Inc | — | Other Technology | Series B | $74.9M | $765.4M | 2009 |
| Kona Medical, Inc. | — | Biotechnology | Series B | $61.6M | $396.9M | 2010 |
| WindMIL Therapeutics, Inc. | — | Biotechnology | Series B | $44.9M | $72.4M | 2016 |
| SonoThera, Inc. | — | Biotechnology | Series B | $30.4M | $550.2M | 2022 |
| Tobira Therapeutics, Inc. | — | Biotechnology | Series A | $23.2M | $513.3M | 2010 |
| ThirdLaw Molecular, Inc. | — | Biotechnology | Series A | $5.5M | $16.4M | 2025 |
| Oceana Therapeutics, Inc. | — | Pharmaceuticals | Seed | $3.0M | $114.1M | 2008 |
| Cortria Corp | — | Pharmaceuticals | Seed | $1.8M | $70.0M | 2009 |
| Nanothera Corp | — | Other Health Care | Seed | $1.3M | $32.2M | 2010 |
Brian Halak at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Halak on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Cohn | 2 | 10 |
| Mark Brooks | 2 | 5 |
| Michael Gertner | 2 | 2 |
| Ryan Drant | 1 | 24 |
| Steven Gillis | 1 | 23 |
| Asish Xavier | 1 | 18 |
| James Taylor | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Adele Oliva | 1 | 9 |
| Stephen Reeders | 1 | 9 |
| Brian Dovey | 1 | 7 |
| Robert More | 1 | 7 |
| James Sapirstein | 1 | 7 |
| Henry A. Plain, Jr. | 1 | 7 |
| Guido Neels | 1 | 7 |
| Reza Zadno | 1 | 7 |
| Immanuel Thangaraj | 1 | 6 |
| David Scheer | 1 | 6 |
| Eric Heil | 1 | 5 |
| Hank Plain | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.